Dawnzera

News

An EMA nod for Otsuka's Dawnzera offers EU patients with HAE a drug that can be self-administered by patients with up to eight weeks between doses.

News

Ionis gets FDA nod for its HAE attack prophylactic treatment Dawnzera, offering less frequent dosing than its rivals.

News

A research consortium that aims to make the UK a leader in AI-driven drug discovery, OpenBind, has hit its first major milestone.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.